HOME >> BIOLOGY >> NEWS
ActoGenix raises 11.5 million in series A stock financing

Ghent, Belgium - ActoGeniX NV, a recently founded biopharmaceutical company, announced the successful closing of its Series A financing round, raising 11.5 million (~US$15 million) from a syndicate of leading life sciences investors. The transaction was co-led by GIMV (Antwerp, Belgium) and Life Sciences Partners (LSP, Amsterdam, The Netherlands), with Biotech Fund Flanders also participating. ActoGeniX is a spin-off from the Flanders Interuniversity Institute of Biotechnology (VIB) and Ghent University and was founded last June with seed capital from GIMV, VIB and individuals of the management team.

This financing will allow ActoGeniX to initiate development of a pipeline of therapeutic products based on its TopActTM technology platform. TopActTM is a proprietary delivery system comprising living non-pathogenic micro-organisms for the oral administration of biopharmaceuticals. VIB and Ghent University, the original inventors of this technology, transferred to ActoGeniX the TopActTM patent portfolio. ActoGeniX' products will address a broad range of diseases, including gastrointestinal diseases, auto-immunity, allergy and metabolic diseases. The Company's lead product for the treatment of Crohn's disease has already been successfully tested in patients.

Dr. Mark Vaeck, who joined the company as CEO, brings considerable experience in the start-up and growth of biotech businesses in Europe and the USA. In his former position, as the co-founder and CEO of Ablynx NV (Ghent, Belgium) he raised 30 million in equity financing and concluded several corporate deals with major pharmaceutical companies. Dr. Bernard Coulie joins ActoGeniX as Vice President Research & Development coming from Johnson & Johnson Europe where he held the position of Therapeutic Area Leader Internal Medicine. Dr. Lothar Steidler, the principal inventor of the TopAct technology, will become Director Technology Development at ActoGeniX.

C
'"/>

Contact: Sooike Stoops
info@vib.be
329-244-6611
VIB, Flanders Interuniversity Institute of Biotechnology
19-Sep-2006


Page: 1 2

Related biology news :

1. New UA / private partnership appraises climate and environmental risks by address
2. Potential genetic testing for substance abuse raises hope, concern
3. Study shows how protein raises antibody output
4. Farm study raises doubts about new approach to swine-disease control
5. Ethiopian development raises birth rate
6. Ethiopian water programme raises birth rate; viral encephalitis study
7. DMSO raises a stink at sewage treatment plants
8. Oxytocin raises aggression, cuts anxiety during lactation; similar effects on virgin rats
9. Air pollution raises risk for dangerous arrhythmias among people with ICDs
10. Mutation in clams protects against paralytic shellfish poisoning but raises human health risk
11. UF science discovery raises questions about origin of African mammals

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/12/2020)... ... August 11, 2020 , ... Both ... NJ, have entered into license agreements with Housey Pharma’s HMI subsidiary to gain ... and J&J have annual Research and Development spending in excess of US $10 ...
(Date:8/7/2020)... SAN FRANCISCO (PRWEB) , ... August 06, 2020 ... ... the life sciences industry, is pleased to announce that Eric Chen and Jessica ... Vice President of Product Management & Strategy, respectively. , Eric Chen heads development ...
(Date:8/5/2020)... Fla. (PRWEB) , ... August 05, 2020 , ... Regenative ... cover two new innovations, CoreText™ and ProText™, making them the first Wharton’s jelly allografts ... defect using a syringe. The company’s solutions are the first Wharton’s jelly allograft product ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... August 12, 2020 , ... Inc. magazine ... global leader in FDA compliance consulting has been named on its annual Inc. ... list represents a unique look at the most successful companies within the American ...
(Date:8/3/2020)... ... , ... Introducing Ardent Animal Health – MediVet Biologics rebrands company and positions ... as MediVet Biologics since its formation in 2016, the company is relaunching itself under ... build on its base of innovative therapies for osteoarthritis and cancer. , ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
(Date:7/31/2020)... ... , ... eSource has long been touted as the solution to high data ... the reasons it did not take off as quickly as people initially expected, and ... moving towards capturing data electronically for clinical trials and then repurposing it for downstream ...
Breaking Biology Technology:
Cached News: